Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data
Australasian Journal of Dermatology · 2023
DOI: 10.1111/ajd.14126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2023. Verfasst von R Sinclair und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biostatistics support was funded by MedicalDirector, on behalf of Pfizer, Medical writing support was funded by Prospection, Australia on behalf of Pfizer, Pfizer Australia.
Abstract (Originalsprache)
Background
Alopecia areata (AA) is a common immune‐mediated non‐scarring hair loss, with a worldwide incidence between 0.57% and 3.8%. The incidence and prevalence of AA in the Australian general population have not been previously reported.
Objective
To describe the incidence and prevalence of AA in Australia using primary care data. A secondary objective was to identify common demographic characteristics, comorbidities and treatment patterns among Australians living with AA.
Methods
We analysed electronic health record data captured from a national clinical practice management software over a 10‐year index period between 2011 and 2020 calendar years, inclusive. The incidence of new‐onset AA and the prevalence of active records with AA were estimated. Differences in incidence by sociodemographic groups, and patterns of treatment were also evaluated.
Results
There were 976 incident AA records. The incidence of new‐onset AA in the total study cohort was 0.278 per 1000 person‐years (95% CI 0.26–0.295). By age, the incidence was highest in the 19‐ to 34‐year‐old age bracket (0.503 per 1000 person‐years: 95% CI 0.453–0.554). AA incidence was lower among females than males (IRR 0.763, p < 0.001, 95% CI 0.673–0.865). Among active records, 520 were prevalent AA records. AA point prevalence at 31/12/2020 was 0.13% (1.26 per 1000 persons; 95% CI 1.15–1.37).
Conclusion
This is the first study to describe the epidemiology (incidence and point prevalence) and management of AA in the Australian primary health‐care population through large‐scale database analysis. Incidence and prevalence findings were consistent with earlier estimates from other regions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Melbourne, Melbourne, Victoria, Australia.
- Epworth HealthCare, East Melbourne, Victoria, Australia.
- Sinclair Dermatology, East Melbourne, Victoria, Australia.
- Prospection Pty Ltd, Sydney, New South Wales, Australia.
- MedicalDirector Clinical, Sydney, New South Wales, Australia.
- Pfizer, Sydney, New South Wales, Australia.
ORCID-Profile: R Sinclair
Förderung
- Biostatistics support was funded by MedicalDirector, on behalf of Pfizer
- Medical writing support was funded by Prospection, Australia on behalf of Pfizer
- Pfizer Australia
Zitieren
APA
Sinclair, R., Eisman, S., Song, W., Heung, B., Surian, C., Lee, C. M. Y., & Witcombe, D. (2023). Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14126
Vancouver
Sinclair R, Eisman S, Song W, Heung B, Surian C, Lee CMY, et al. Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data. Australasian Journal of Dermatology. 2023. doi:10.1111/ajd.14126
BibTeX
@article{Sinclair2023,
author = {Sinclair, R and Eisman, S and Song, W and Heung, B and Surian, C and Lee, C M Y and Witcombe, D},
title = {Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data},
journal = {Australasian Journal of Dermatology},
year = {2023},
doi = {10.1111/ajd.14126}
}
EUVIMED